PMID- 37701037
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230915
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - The functions and regulatory pathways of S100A8/A9 and its receptors in cancers.
PG  - 1187741
LID - 10.3389/fphar.2023.1187741 [doi]
LID - 1187741
AB  - Inflammation primarily influences the initiation, progression, and deterioration 
      of many human diseases, and immune cells are the principal forces that modulate 
      the balance of inflammation by generating cytokines and chemokines to maintain 
      physiological homeostasis or accelerate disease development. S100A8/A9, a 
      heterodimer protein mainly generated by neutrophils, triggers many signal 
      transduction pathways to mediate microtubule constitution and pathogen defense, 
      as well as intricate procedures of cancer growth, metastasis, drug resistance, 
      and prognosis. Its paired receptors, such as receptor for advanced glycation ends 
      (RAGEs) and toll-like receptor 4 (TLR4), also have roles and effects within tumor 
      cells, mainly involved with mitogen-activated protein kinases (MAPKs), NF-kappaB, 
      phosphoinositide 3-kinase (PI3K)/Akt, mammalian target of rapamycin (mTOR) and 
      protein kinase C (PKC) activation. In the clinical setting, S100A8/A9 and its 
      receptors can be used complementarily as efficient biomarkers for cancer 
      diagnosis and treatment. This review comprehensively summarizes the biological 
      functions of S100A8/A9 and its various receptors in tumor cells, in order to 
      provide new insights and strategies targeting S100A8/A9 to promote novel 
      diagnostic and therapeutic methods in cancers.
CI  - Copyright (c) 2023 Zhou, Zhao, Shao, Xu and Zhao.
FAU - Zhou, Huimin
AU  - Zhou H
AD  - State Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of 
      Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute 
      of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Zhao, Cong
AU  - Zhao C
AD  - State Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of 
      Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute 
      of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Shao, Rongguang
AU  - Shao R
AD  - State Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of 
      Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute 
      of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Xu, Yanni
AU  - Xu Y
AD  - NHC Key Laboratory of Biotechnology of Antibiotics, National Center for New 
      Microbial Drug Screening, Institute of Medicinal Biotechnology, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Zhao, Wuli
AU  - Zhao W
AD  - State Key Laboratory of Respiratory Health and Multimorbidity, Key Laboratory of 
      Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute 
      of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230828
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10493297
OTO - NOTNLM
OT  - RAGEs
OT  - S100A8/A9
OT  - TLR4
OT  - cancer
OT  - inflammation
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/09/13 06:42
MHDA- 2023/09/13 06:43
PMCR- 2023/08/28
CRDT- 2023/09/13 03:59
PHST- 2023/03/22 00:00 [received]
PHST- 2023/08/07 00:00 [accepted]
PHST- 2023/09/13 06:43 [medline]
PHST- 2023/09/13 06:42 [pubmed]
PHST- 2023/09/13 03:59 [entrez]
PHST- 2023/08/28 00:00 [pmc-release]
AID - 1187741 [pii]
AID - 10.3389/fphar.2023.1187741 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Aug 28;14:1187741. doi: 10.3389/fphar.2023.1187741. 
      eCollection 2023.